[U.S. Stocks Movement] Arrivent plunges on October 6: FURVENT trial fails and primary endpoints not met
Bitget异动解读2026/10/06 13:35Arrivent October 6th: Major Decline Analysis
Keywords: FURVENT trial failure, primary endpoint not achieved
On October 6, 2026, ArriVent announced that the FURVENT Phase III trial did not achieve the primary endpoint of progression-free survival as assessed by a blinded independent central review. The median progression-free survival was 11.0 months in the firmonertinib 240mg group, compared to 9.5 months in the control group. The difference was not statistically significant, with a p-value of 0.0654. The company stated it is currently evaluating subsequent development strategies.
(Disclaimer: This content was generated by AI technology by collecting and summarizing public information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple adjusts 2026 fall new device orders, increases iPhone Duo order by 30%
ASML to raise prices of equipment parts in Korea by 10% starting January next year
According to Korean media reports, ASML, the world’s largest semiconductor equipment manufacturer, will implement a uniform 10% price increase on replacement parts for equipment supplied in Korea. The new prices will take effect starting from January next year, and the increase covers all components of both EUV and DUV lithography machines. Industry insiders revealed that in early last month, ASML's headquarters had already expressed its intention to raise prices to Samsung Electronics and SK Hynix through its Korean branch. The adjustment was finalized after negotiations with the procurement departments of both companies.
Crypto prices
More
